Eleven Biotherapeutics (EBIO) Reports Q1 Loss of $0.25

Eleven Biotherapeutics (NASDAQ: EBIO) reported Q1 EPS of ($0.25), versus ($0.39) reported last year. Revenue for the quarter came in at $400 thousand, versus $200 thousand reported last year.

Cash Position: Cash and cash equivalents were $20.3 million as of March 31, 2017, compared to $25.3 million as of December 31, 2016.

For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• GitLab Inc (GTLB) Tops Q2 EPS by 7c, Beats on Revenue
• Berenberg Starts Avio (AVIO:IM) at Hold